Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Acetamide, N-[2-(4-bromophenyl)ethyl]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

105871-04-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 105871-04-3 Structure
  • Basic information

    1. Product Name: Acetamide, N-[2-(4-bromophenyl)ethyl]-
    2. Synonyms:
    3. CAS NO:105871-04-3
    4. Molecular Formula: C10H12BrNO
    5. Molecular Weight: 242.115
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 105871-04-3.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: Acetamide, N-[2-(4-bromophenyl)ethyl]-(CAS DataBase Reference)
    10. NIST Chemistry Reference: Acetamide, N-[2-(4-bromophenyl)ethyl]-(105871-04-3)
    11. EPA Substance Registry System: Acetamide, N-[2-(4-bromophenyl)ethyl]-(105871-04-3)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 105871-04-3(Hazardous Substances Data)

105871-04-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 105871-04-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,8,7 and 1 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 105871-04:
(8*1)+(7*0)+(6*5)+(5*8)+(4*7)+(3*1)+(2*0)+(1*4)=113
113 % 10 = 3
So 105871-04-3 is a valid CAS Registry Number.

105871-04-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name N-acetyl-2-(4-bromophenyl)ethylamine

1.2 Other means of identification

Product number -
Other names N-[2-(4-bromo-phenyl)-ethyl]-acetamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:105871-04-3 SDS

105871-04-3Downstream Products

105871-04-3Relevant articles and documents

Structure-Functional-Selectivity Relationship Studies of Novel Apomorphine Analogs to Develop D1R/D2R Biased Ligands

Liu, Chuan,Park, Hyejin,Urs, Aarti N.,Urs, Nikhil M.,Wang, Qiu,Zimmerman, Joseph

, (2020/02/06)

Loss of dopamine neurons is central to the manifestation of Parkinson's disease motor symptoms. The dopamine precursor L-DOPA, the most commonly used therapeutic agent for Parkinson's disease, can restore normal movement yet cause side-effects such as dyskinesias upon prolonged administration. Dopamine D1 and D2 receptors activate G-protein- A nd arrestin-dependent signaling pathways that regulate various dopamine-dependent functions including locomotion. Studies have shown that shifting the balance of dopamine receptor signaling toward the arrestin pathway can be beneficial for inducing normal movement, while reducing dyskinesias. However, simultaneous activation of both D1 and D2Rs is required for robust locomotor activity. Thus, it is desirable to develop ligands targeting both D1 and D2Rs and their functional selectivity. Here, we report structure-functional-selectivity relationship (SFSR) studies of novel apomorphine analogs to identify structural motifs responsible for biased activity at both D1 and D2Rs.

A focused fragment library targeting the antibiotic resistance enzyme - Oxacillinase-48: Synthesis, structural evaluation and inhibitor design

Akhter, Sundus,Lund, Bjarte Aarmo,Ismael, Aya,Langer, Manuel,Isaksson, Johan,Christopeit, Tony,Leiros, Hanna-Kirsti S.,Bayer, Annette

supporting information, p. 634 - 648 (2018/01/19)

β-Lactam antibiotics are of utmost importance when treating bacterial infections in the medical community. However, currently their utility is threatened by the emergence and spread of β-lactam resistance. The most prevalent resistance mechanism to β-lactam antibiotics is expression of β-lactamase enzymes. One way to overcome resistance caused by β-lactamases, is the development of β-lactamase inhibitors and today several β-lactamase inhibitors e.g. avibactam, are approved in the clinic. Our focus is the oxacillinase-48 (OXA-48), an enzyme reported to spread rapidly across the world and commonly identified in Escherichia coli and Klebsiella pneumoniae. To guide inhibitor design, we used diversely substituted 3-aryl and 3-heteroaryl benzoic acids to probe the active site of OXA-48 for useful enzyme-inhibitor interactions. In the presented study, a focused fragment library containing 49 3-substituted benzoic acid derivatives were synthesised and biochemically characterized. Based on crystallographic data from 33 fragment-enzyme complexes, the fragments could be classified into R1 or R2 binders by their overall binding conformation in relation to the binding of the R1 and R2 side groups of imipenem. Moreover, binding interactions attractive for future inhibitor design were found and their usefulness explored by the rational design and evaluation of merged inhibitors from orthogonally binding fragments. The best inhibitors among the resulting 3,5-disubstituted benzoic acids showed inhibitory potential in the low micromolar range (IC50 = 2.9 μM). For these inhibitors, the complex X-ray structures revealed non-covalent binding to Arg250, Arg214 and Tyr211 in the active site and the interactions observed with the mono-substituted fragments were also identified in the merged structures.

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties

Bruncko, Milan,McClellan, William J.,Wendt, Michael D.,Sauer, Daryl R.,Geyer, Andrew,Dalton, Christopher R.,Kaminski, Michele A.,Weitzberg, Moshe,Gong, Jane,Dellaria, Joseph F.,Mantei, Robert,Zhao, Xumiao,Nienaber, Vicki L.,Stewart, Kent,Klinghofer, Vered,Bouska, Jennifer,Rockway, Todd W.,Giranda, Vincent L.

, p. 93 - 98 (2007/10/03)

A series of non-amide-linked 6-substituted-2-naphthamidine urokinase plasminogen activator (uPA) inhibitors are described. These compounds possess excellent binding activities and selectivities with significantly improved pharmacokinetic profiles versus p

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 105871-04-3